Clinical Trial for Treatment of Ulcerative Colitis Gets Positive Report

Clinical Trial for Treatment of Ulcerative Colitis Gets Positive Report
Synergy Pharmaceuticals, a company that discovers and develops compounds involving uroguanylin analogs for the treatment of inflammatory bowel disease (IBD) and functional gastrointestinal disorders, recently disclosed positive Phase 1b clinical trial data on dolcanatide, a uroguanylin analog. Uroguanylin is an amino acid peptide that regulates the transport of water and electrolytes in the intestine and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

4 comments

  1. Patrick Lever says:

    I am a70 year old male suffering from ulcritive colitis for many years, I’m on infliximab at the moment but does not seem to help me now as mutch as it used to, if you need more people to test new drugs I would be available to help you wherever I can. Yours willing to help pat lever.

Leave a Comment

Your email address will not be published. Required fields are marked *